Dyax Corp. (NASDAQ: DYAX) announced today that executive management will participate in the Leerink Swann Global Healthcare Conference, being held February 13-14, 2013, at the Waldorf Astoria in New York City. Gustav Christensen, President and Chief Executive Officer of Dyax, will present on Thursday, February 14 at 11:00 AM (ET). Mr. Christensen will provide a corporate update regarding the Company’s key value drivers – KALBITOR® (ecallantide) and the angioedema portfolio, as well as the Licensing and Funded Research Program (LFRP).
